-
41.发明公开Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine 有权Tumorassoziierte Peptide，die HLA Klasse I oder II-Molekülebinden，und anti-Tumor Impfstoffe
公开(公告)号：EP1760089A1
公开(公告)日：2007-03-07
申请号：EP05019255.8
申请日：2005-09-05
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可以用于引发抗肿瘤免疫应答的疫苗组合物中的两种来自人类肿瘤细胞系HLA II类分子的新肽。
-
公开(公告)号：EP1734049A1
公开(公告)日：2006-12-20
申请号：EP06015806.0
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： Die Erfindung betrifft ein Tumor-assoziiertes Peptid mit einer Aminosäuresequenz, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID-Nr. 1 bis SEQ ID-Nr. 79 aus dem beiliegenden Sequenzprotokoll, wobei das Peptid die Fähigkeit aufweist, an ein Molekül des menschlichen Haupt-Histokompatibilitäts-Komplexes (MHC) Klasse-I zu binden. Die Erfindung betrifft darüber hinaus die Verwendung der Peptide zur Herstellung eines Arzneimittels und zur Behandlung von Tumorerkrankungen. Ferner wird eine pharmazeutische Zusammensetzung beschrieben, die mindestens eines der Peptide aufweist.
摘要翻译： 本发明涉及具有选自下组的氨基酸序列的肿瘤相关肽：SEQ ID NO.1。 1至SEQ ID NO.1。 其中所述肽具有结合人类主要组织相容性复合体（MHC）I类分子的能力。 本发明还涉及所述肽在制造药物和治疗肿瘤疾病中的用途。 进一步描述了包含至少一种肽的药物组合物。
-
公开(公告)号：EP1734048A1
公开(公告)日：2006-12-20
申请号：EP06015805.2
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： Die Erfindung betrifft ein Tumor-assozüertes Peptid mit einer Aminosäuresequenz, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID-Nr. 1 bis SEQ ID-Nr. 79 aus dem beiliegenden Sequenzprotokoll, wobei das Peptid die Fähigkeit aufweist, an ein Molekül des menschlichen Haupt-Histokompatibilitäts-Komplexes (MHC) Klasse-I zu binden. Die Erfindung betrifft darüber hinaus die Verwendung der Peptide zur Herstellung eines Arzneimittels und zur Behandlung von Tumorerkrankungen. Ferner wird eine pharmazeutische Zusammensetzung beschrieben, die mindestens eines der Peptide aufweist.
摘要翻译： 具有79个序列中任何一个的重组的肿瘤相关肽（I）是新的。 （I）可以结合人类主要组织相容性复合物（MHC）的I类分子。 还包括以下独立权利要求：（1）编码（I）的核酸（II）; （2）含有（II）的载体; 和（3）通过掺入（II）或（2）的载体修饰以表达（I）的细胞。 活动：细胞抑制。 动作机制：疫苗; 诱导细胞毒性T淋巴细胞（CTL）。 从外周血中分离树突状细胞（50万），并用50μg/ ml的肽（1）孵育2小时，然后洗涤并与250万个自体外周血单核细胞（PBMC）孵育7天。 在第1,3和5天，用白细胞介素-2（1ng / ml）再次刺激细胞，然后在标准的51铬释放试验中，以效应物：靶标比例为30:1，对各种癌细胞进行细胞毒性试验。 HCT 116胃癌细胞的典型特异性裂解评分超过30％ A498肾癌细胞超过60％; 约40％为MEL1479黑素瘤，约50％为MCF-7乳腺癌细胞。 Tyr-Val-Asp-Pro-Val-Ile-Thr-Ser-Ile（1）。
-
44.发明公开
公开(公告)号：EP4321172A3
公开(公告)日：2024-08-21
申请号：EP23216397.2
申请日：2016-07-05
发明人： Fritsche, Jens , Schoor, Oliver , Weinschenk, Toni , Mahr, Andrea , Singh, Harpreet , SONG, Colette
IPC分类号： C07K14/47 , C07K14/635 , A61K39/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/0011 , A61K39/001152 , A61P35/00 , A61K39/00 , A61K39/4644 , C12N5/0636 , C12N5/0638 , A61K39/4611 , A61K35/17
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
45.发明公开
公开(公告)号：EP3915577A1
公开(公告)日：2021-12-01
申请号：EP21171324.3
申请日：2017-02-28
发明人： Mahr, Andrea , Weinschenk, Toni , Song, Colette , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
46.发明授权
公开(公告)号：EP3363456B1
公开(公告)日：2020-08-05
申请号：EP18156634.0
申请日：2011-03-15
-
47.发明公开
公开(公告)号：EP3545965A2
公开(公告)日：2019-10-02
申请号：EP19170191.1
申请日：2015-12-16
发明人： Weinschenk, Toni , Mahr, Andrea , Fritsche, Jens , Müller, Phillip , Wiebe, Anita , Missel, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
公开(公告)号：EP3042914B1
公开(公告)日：2018-07-04
申请号：EP15193843.8
申请日：2008-07-25
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Walter, Steffen , Lewandrowski, Peter
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.
-
49.发明公开
公开(公告)号：EP3058947A3
公开(公告)日：2016-11-30
申请号：EP16156192.3
申请日：2011-03-15
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
50.发明授权
公开(公告)号：EP2567707B1
公开(公告)日：2016-10-05
申请号：EP12187307.9
申请日：2008-07-25
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Walter, Steffen , Lewandrowski, Peter
CPC分类号： A61K39/0011 , A61K38/193 , A61K45/06 , A61K2039/5158 , A61K2039/53 , A61K2039/572 , C07K14/4748 , A61K2300/00
摘要： The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer.
-
-
-
-
-
-
-
-
-
搜索结果
84 条记录 (耗时 0.03 秒)
